Genevation

What Genevation does

Genevation LTD is a privately held, pre-clinical-stage biotechnology company founded in 2022 in London, United Kingdom, and headquartered at the Stevenage Bioscience Catalyst. The company is developing personalized mRNA cancer vaccines using an AI-driven, cell-free manufacturing platform that it claims can produce a patient-specific vaccine in approximately two weeks—substantially faster than conventional personalized-vaccine timelines. Genevation's pipeline is focused on prophylactic and therapeutic vaccines for lung, colon, and skin cancers, with pre-clinical studies completed in mice and the company now positioning for Phase 1 clinical trials.

The core technology consists of two integrated platforms: (1) an AI-driven Neoantigen Identification Platform that analyses genetic mutations from patient biopsies to identify tumor-specific neo-antigens, and (2) a cell-free manufacturing platform used to produce the corresponding mRNA vaccine. Genevation processes patient biopsy genetic data through AI analysis to identify unique tumor antigens, which are then used as the basis for personalized mRNA constructs. The company describes a team of 1–10 professionals with backgrounds in science, biomedical engineering, bioinformatics, and AI development, and operates a secondary contact location at BioLabs San Diego in preparation for a planned US market entry by 2026.

Genevation is pre-revenue and has not yet established a commercial pricing or revenue model. Its go-to-market will initially run through Phase 1 clinical trial sites and, longer term, through pharmaceutical partnerships or direct medical-provider channels. The company is founder-led by Dr. Prasun Chakraborty, an ex-Harvard fellow with 18+ years of experience in IVT, cancer biology, and RNA biology, and it has raised approximately $505,320 to date in disclosed funding (a single 2024 round). Genevation relies primarily on LinkedIn and its own website for outreach, with NVIDIA listed as a visible partner on its site alongside its two facility partners (Stevenage Bioscience Catalyst and BioLabs San Diego).

Name

Genevation

Legal name

Genevation LTD

Website

https://genevation.co.uk

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Genevation LTD is a UK-based, pre-clinical-stage biotechnology company developing personalized mRNA cancer vaccines for lung, colon, and skin cancers using an AI-driven neoantigen identification platform combined with cell-free manufacturing, targeting patient-specific oncology indications.

Ownership category

akta.pro rank

Product category

Personalized Cancer Vaccines / Oncology Biotechnology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

akta.pro secondary industries

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

Keywords

• Personalized cancer vaccines
• MRNA therapeutics
• Neoantigen identification
• Cell-free manufacturing
• Precision oncology

Headquarters

HQ city

Stevenage

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. mRNA Cancer Vaccines: Pre-revenue biotech company developing personalized mRNA cancer vaccines. Revenue model not yet established as company is in pre-clinical stage preparing for Phase 1 clinical trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Genevation is a pre-clinical biotechnology company that develops personalized mRNA cancer vaccines using an AI-driven neoantigen identification platform combined with a cell-free manufacturing approach. The company targets lung, colon, and skin cancers by analyzing patient biopsy genetic data to identify tumor-specific neoantigens and producing tailored vaccines in approximately two weeks. Its pipeline is advancing toward Phase 1 clinical trials with planned expansion into additional cancer types.

Product overview

Genevation offers a unified platform for personalized mRNA cancer vaccines, combining their AI-Driven Neoantigen Identification Platform with cell-free vaccine manufacturing technology. The platform processes patient biopsy genetic data through AI-driven analysis to identify tumor-specific neoantigens, which are then used to develop personalized mRNA cancer vaccines. The company targets lung, colon, and skin cancers, with plans to expand to rare cancers. Their pre-clinical pipeline is advancing toward Phase 1 clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• Personalized mRNA Cancer Vaccines AI-driven, cell-free mRNA-based therapeutic and prophylactic vaccines developed for individual cancer patients by identifying tumor-specific neoantigens from biopsy data; designed to treat lung, colon, and skin cancers with planned expansion to additional cancer types.
• AI-Driven Neoantigen Identification Platform Proprietary AI platform that analyzes genetic mutations from patient biopsies to identify tumor-specific neoantigens—unique proteins on cancer cell surfaces—to guide the design of personalized mRNA cancer vaccines. Enables precision oncology targeting for individual tumor profiles.

Quantifiable outcome

• Personalized mRNA cancer vaccines developed in two weeks

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Stevenage Bioscience CatalystcoreStrategic or Co-development PartnerHost organization providing laboratory and innovation space for Genevation's research operations. Located at Gunnels Wood Rd, Stevenage SG1 2FX.
• BioLabs San DiegocoreStrategic or Co-development PartnerPartner facility providing lab space for Genevation's planned US expansion. Located at 9276 Scranton Road Suite 500, San Diego, CA 92121.

Scale indicators3 records

Recent moves1 record

Expansion highlights5 records

Broad incumbents

• BioNTech: BioNTech is the leading mRNA-based personalized cancer vaccine company (BNT122/Autogene cevumeran in partnership with Roche/Genentech), with a FixVac and individualized neoantigen vaccine platform that directly competes with Genevation's approach.
• Moderna: Moderna operates a leading mRNA technology platform and is actively expanding into oncology with personalized neoantigen vaccines (mRNA-4157/V940 with Merck). It is a directly comparable mRNA vaccine developer with deeper resources and clinical data.

Direct peers

• Gritstone bio: Gritstone bio develops personalized neoantigen cancer vaccines (SLATE and GRANITE programs) using self-amplifying mRNA and adenoviral vectors with AI-driven neoantigen prediction, making it one of the closest direct comparables to Genevation.
• CureVac: CureVac is a clinical-stage mRNA technology company developing therapeutic cancer vaccines and prophylactic vaccines, directly comparable as an mRNA platform peer in oncology.
• Achilles Therapeutics: Achilles Therapeutics develops personalized neoantigen-based therapies for cancer using AI-guided tumor analysis and patient-specific manufacturing, sharing the AI neoantigen discovery and personalized manufacturing model with Genevation.
• Neon Therapeutics: Neon Therapeutics was a pioneer in AI-driven neoantigen-based personalized cancer vaccines (NEO-PV-01) before being acquired by BioNTech. It represents the archetype of the AI-personalized cancer vaccine model Genevation is pursuing.

Emerging players

• Providence Therapeutics: Providence Therapeutics is a clinical-stage mRNA therapeutics company developing personalized cancer vaccines, making it a comparable early-stage peer in the personalized mRNA oncology space.
• Personalis: Personalis combines genomic sequencing and AI-driven analytics to support personalized oncology applications including neoantigen identification, providing a comparable AI-driven precision oncology platform.
• Tempus AI: Tempus AI applies AI and machine learning to large-scale clinical and molecular data for precision oncology, including applications in identifying actionable biomarkers and treatment selection comparable to Genevation's AI-driven neoantigen platform.
• Transgene: Transgene develops therapeutic cancer vaccines and immunotherapies (including TG4050, a personalized neoantigen vaccine using AI), making it a closely comparable European peer in personalized cancer vaccines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/genevation-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genevation